Plasma Amyloid-β in Patients with Tangier Disease

Article type: Research Article

Authors: Shahim, Pashtun^{a; 1; *} | Bochem, Andrea E.^{b; 1} | Mattsson, Niklas^a | Lautner, Ronald^a | Blennow, Kaj^a | Hovingh, G. Kees^b | Motazacker, M. Mahdi^b | Zetterberg, Henrik^{a; c}

Affiliations: [a] Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry, Sahlgrenska University Hospital/Mölndal, Sweden | [b] Academic Medical Center, Department of Experimental Vascular Medicine, Amsterdam, The Netherlands | [c] UCL Institute of Neurology, Queen Square, London, UK

Correspondence: [*] Correspondence to: Pashtun Shahim, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, S-431 80 Mölndal, Sweden. Tel.: +46 762704584; Fax: +46 31 34324 26; E-mail: pashtun.shahim@neuro.gu.se.

Note: [1] These authors contributed equally to this study.

Abstract: Tangier disease (TD) is a rare genetic disorder caused by mutations in the ATP-binding cassette transporter A1 (ABCA1) gene, which results in impaired cellular cholesterol efflux and high-density lipoprotein cholesterol deficiency. Animal and in vitro studies indicate that ABCA1 is involved in the production of amyloid-β (Aβ), a pivotal protein in Alzheimer's disease. We here examined whether plasma Aβ levels are altered in TD patients. Plasma from 5 TD patients and 5 controls were analyzed for Aβ1-40, Aβ1-42, AβX-40, and AβX-42 but no differences were found. In conclusion, loss of ABCA1 function may not have any profound effect on Aβ metabolism in humans, at least not in the periphery, as reflected by plasma Aβ levels.

Keywords: Alzheimer's disease, amyloid-β, biological markers, plasma, Tangier disease

DOI: 10.3233/JAD-122425

Journal: Journal of Alzheimer's Disease, vol. 35, no. 2, pp. 307-312, 2013